Experimental cocktail aims to tackle tough lymphoma
NCT ID NCT04049825
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial tested an experimental drug called OPB-111077 combined with two standard chemotherapy drugs (bendamustine and rituximab) in 36 people whose diffuse large B-cell lymphoma had come back or stopped responding to treatment. The main goal was to check the safety and find the right dose, not to measure how well it works. The study is already completed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- OPB-111077 (an experimental drug) combined with bendamustine and rituximab (standard chemotherapies)
- What this could lead to
- If successful, this could point toward a new combination treatment option for people with relapsed or refractory diffuse large B-cell lymphoma.
- What could go wrong
- This is a very early (Phase 1) trial with only 36 participants, focused on safety and dosing. It is not designed to prove effectiveness, and the combination may cause significant side effects or fail to work in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Yamagata University Hospital
Yamagata, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for hard-to-treat lymphoma: experimental drug combo enters phase 3 trial
- New combo offers hope for aggressive lymphoma in diverse patients
- Double punch: CAR-T cells followed by antibodies may boost lymphoma remission
- New pill shows promise for Hard-to-Treat lymphoma
- New hope for tough lymphoma: targeted drug shows promise
- New drug combo aims to tackle tough lymphoma